Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7916712 | 1.00 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2DDAH1TSHR | |
| SCHEMBL4910662 | 1.00 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2DDAH1TSHR | |
| SCHEMBL10386531 | 0.83 | ALOX15 (0.39) | HCAR2KEAP1NFE2L2TSHRHSD17B10 | |
| SCHEMBL10386530 | 0.83 | ALOX15 (0.39) | HCAR2KEAP1NFE2L2TSHRHSD17B10 | |
| SCHEMBL11471057 | 0.81 | HCAR2 (0.36) | HCAR2KEAP1NFE2L2TSHRHSD17B10 | |
| SCHEMBL11471056 | 0.81 | HCAR2 (0.36) | HCAR2KEAP1NFE2L2TSHRHSD17B10 | |
| SCHEMBL4807131 | 0.81 | NPSR1 (0.48) | HCAR2DDAH1HSD17B10NPSR1 | |
| SCHEMBL4807139 | 0.81 | NPSR1 (0.48) | HCAR2DDAH1HSD17B10NPSR1 | |
| SCHEMBL4675106 | 0.79 | — | — | |
| SCHEMBL13531532 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021070-A1 | PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | US | disclosed |
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1678138-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042488-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20020193605-A1 | New dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1191022-A1 | NOVEL DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-0565059-B1 | Indole derivative | KYOWA HAKKO KOGYO KK (JP) | 1996-07-31 | — | — | EP | disclosed |
| US-5344938-A | Indole 3-carboxylic acid derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-09-06 | — | — | US | disclosed |
| EP-0565059-A1 | Indole derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-10-13 | — | — | EP | disclosed |
| US-5198439-A | Hypotensive agents, congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-03-30 | — | — | US | disclosed |
| US-5130318-A | Hypotensive agents and for treatment of congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-14 | — | — | US | disclosed |
| EP-0453210-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1991-10-23 | — | — | EP | disclosed |
| EP-0177965-B1 | NOVEL OXA- AND THIADIAZOLYL DERIVATIVES AND THEIR USE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-03-21 | — | — | EP | disclosed |
| US-4705786-A | Novel oxadiazolyl-1,4-dihydropyridines useful as antihypertensive agents | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-11-10 | — | — | US | disclosed |
| EP-0177965-A2 | Novel oxa- and thiadiazolyl derivatives and their use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
| EP-0001054-A2 | 2-Pyridyl-1,4-dihydropyridine derivatives, methods for their preparation and their pharmaceutical use | BAYER AG (DE) | 1979-03-21 | — | — | EP | disclosed |
| US-4020178-A | 1,4-Dihydropyridine esters used as coronary dilators and anti-hypertensives | BAYER AKTIENGESELLSCHAFT (DT) | 1977-04-26 | — | — | US | disclosed |
| US-3974278-A | 1,4-Dihydropyridine esters | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-10 | — | — | US | disclosed |
| US-3971796-A | 1,4-Dihydropyridine esters | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021070-A1 | PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | CNR1, CNR2, GPR18 | HCAR2 191/4885KEAP1 1992/4885NFE2L2 3513/4885 |
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | HCAR2 896/4885KEAP1 258/4885NFE2L2 551/4885 |
| US-20020193605-A1 | New dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | HCAR2 507/4885KEAP1 2334/4885NFE2L2 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.